An international research team, headed by Joseph Vinetz, MD, professor of medicine at University of California, San Diego School of Medicine and director of the UC San Diego Center for Tropical Medicine and Travelers Health, has been awarded a 5-year, …
Mayor Kevin Faulconer visits Sanford Burnham Prebys Medical Discovery Institute.
Electrical engineers at the University of California, San Diego demonstrated a new wireless communication technique that works by sending magnetic signals through the human body. The new technology could offer a lower power and more secure way to commu…
Polio Virus Accidentally Discharged by GlaxoSmithKline Anthrax Accidentally Shipped to Numerous Labs New RNA Vaccines are Viewed as Much Safer and Better Polio Virus Accidental Discharge The genesis of this blog about safer, better vaccines using RNA instead of … Continue reading →
SAN DIEGO, Sept. 1, 2015 /PRNewswire/ — Agena BioscienceTM today announced the establishment of a subsidiary in Shanghai, a commercial and financial hub from which many biotech and life science firms serve the growing number of genomic testing laboratories in mainland China.
“The Chinese market represents a significant portion of Agena Bioscience’s global sales with almost sixty MassARRAY® Systems installed to date. Direct presence within China will allow us to expand our reach and foster a high degree of engagement with our local customers in that region,” said Pete Dansky, CEO.
Bob Wang has joined Agena Bioscience as its Vice President and General Manager, Greater China. Bob most recently was Marketing Director for QIAGEN, responsible for leading the development of its molecular diagnostics and life science commercial strategies. Prior to this, Bob held senior positions encompassing Business Development, Marketing, Sales, and Regulatory Affairs at Hologic, Life Technologies, Applied Biosystems, and the Chinese Human Genome Center.
“We are delighted to have Bob leading our Greater China organization. His experience in both clinical diagnostics and life science research will help drive Agena Bioscience’s strategy and commercial execution in China,” said Dansky.
The MassARRAY System by Agena Bioscience provides a mid-plex technology for targeted profiling of 10’s to 100s of genetic markers. The system offers a practical solution for today’s clinical and translational research labs with improvements in cost, throughput, reimbursement, and ease of use over alternative methods. The MassARRAY System is used in 37 countries worldwide with an installed base of 350+ systems.
About Agena Bioscience
Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. The MassARRAY System is intended for research use only, and not intended for use in diagnostic procedures.
SOURCE Agena Bioscience
API Integration Showcase at Connected Health Summit to Demonstrate Best Practices and Use Cases for Connected Health Devices and Services
DALLAS, TX–(Marketwired – Sep 1, 2015) – Parks Associates announced today the addition of the API Integration Showcase at the upcoming Connected Health Summit: Engaging Consumers, September 9-10 at the Omni Hotel in San Diego. The two-day executive conference will host over 250 executives focused on consumer-centric connected health solutions, with keynotes from AT&T, Cerner, CVS Health, Kaiser Permanente, and Humana. The API Integration Showcase will feature new connected health use cases and discuss best practices and lessons learned from the API experience.
AV1 Group Continues to Enhance the VaporHighUSA.com Product Line With the Addition of VaporHighUSA CBD Oils
LA JOLLA, CA–(Marketwired – Sep 1, 2015) – AV1 Group, Inc. ( OTC PINK : AVOP ) is pleased to announce that the Company continues to build VaporHighUSA.com’s product line with the addition of CBD OIL under the VaporHighUSA label. Cannabidiol (CBD) i…
For certain parts of the population, “summer” is a verb, and in the U.S., one does it until Labor Day. One more week, then, before sunburned financial types return to their desks and…
[[Click headline to continue reading.]]
CA-Del Mar, San Diego Biotech Company is seeking a talented Accounting Assistant to add to their team. This position will require the selected candidate to perform the following duties. Review of accuracy and initiate customer invoice posting into Comp…
SAN DIEGO, CA–(Marketwired – Sep 1, 2015) – Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Russian Patent No. 2554814, titled: “Compositions for drug administration,” covers fast acting drug formulations utilizing Aegis’ Intravail® transmucosal absorption enhancer technology. The Aegis Intravail-based formulation achieves clinically effective drug levels in about 2 minutes — about 20 times faster than the currently available nasal triptan product.